Skip to main content

Table 1 Comparison of demographic and clinical characteristics in terms of gender

From: Association of apolipoprotein E (APOE) polymorphisms with warfarin maintenance dose in a northern Han Chinese population

Variable

Males

Females

P-value

Age (years)

54.95±11.15

56.42±9.08

0.328

Smoking (n, %)

8(8.6)

0(0)

0.004

Drinking (n, %)

8(8.6)

0(0)

0.004

BSA (m2)

1.78±0.16

1.61±0.13

<0.001

BMI (kg/ m2)

24.20±3.18

24.01±3.27

0.686

Weight (kg)

70.12±10.81

61.43±9.14

<0.001

Height (cm)

170.08±5.61

159.89±5.15

<0.001

Hypertension (n, %)

21(22.6)

12(12.9)

0.084

Hyperlipidemia (n, %)

10(10.8)

8(8.6)

0.620

Diabetes (n, %)

7(7.5)

11(11.8)

0.321

CAD (n, %)

9(9.7)

8(8.6)

0.799

Stroke (n, %)

4(4.3)

4(4.3)

1.000

SBP (mm Hg)*

125 (120–130)

125 (116.5–130)

0.990

DBP (mm Hg)*

74 (64–80)

74 (64–80)

0.737

Triglycerides (mmol/L)*

1.31 (0.86–2.05)

1.30 (0.99–1.87)

0.540

Total cholesterol (mmol/L)

4.72±1.02

4.81±1.13

0.566

LDL-C (mmol/L)

2.92±0.86

2.96±0.91

0.782

HDL-C (mmol/L)

1.11±0.31

1.15±0.32

0.342

FBG (mmol/L)*

5.28 (4.91–5.74)

5.40 (4.97–5.91)

0.398

CRP (mg/L)*

1.01 (0.47–3.35)

1.11 (0.59–3.47)

0.638

BUN (mmol/L)*

6.70 (5.80–7.85)

5.50 (4.70–6.70)

<0.001

SCR (umol/L)

83.25±13.60

69.71±19.93

<0.001

eGFR (ml/min/1.73m2)

94.67±16.52

89.78±19.39

0.066

Amiodarone use (n, %)

2(2.2)

4(4.3)

0.678

Diltiazem use (n, %)

1(1.1)

4(4.3)

0.365

Statins use (n, %)

8(8.6)

5(5.4)

0.388

Dioxin use (n, %)

17(18.3)

16(17.2)

0.848

Insulin use (n, %)

4(4.3)

5(5.4)

0.733

  1. *Continuous variables with skewed distribution were reported as medians (Q1 and Q3); BSA: body surface area; BMI: body mass index; CAD: coronary artery disease; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FBG: fasting blood glucose; CRP: C-reactive protein; BUN: blood urea nitrogen; SCR: serum creatinine; eGFR: glomerular filtration rate